Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
138,100
Employees138,100
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
138,100
Employees138,100

JNJ Key Statistics

Market cap
377.42B
Market cap377.42B
Price-Earnings ratio
17.53
Price-Earnings ratio17.53
Dividend yield
3.18%
Dividend yield3.18%
Average volume
7.24M
Average volume7.24M
High today
$157.50
High today$157.50
Low today
$155.18
Low today$155.18
Open price
$156.69
Open price$156.69
Volume
7.73M
Volume7.73M
52 Week high
$169.99
52 Week high$169.99
52 Week low
$140.68
52 Week low$140.68

JNJ News

Benzinga 22h
Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson & Johnson JNJ will release earnings results for the second quarter, before the opening bell on Wednesday, July 16. Analysts expect the New Brunswick, N...

Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga 2d
What To Expect From Johnson & Johnson's Q2 Earnings - Johnson & Johnson - Benzinga

...

What To Expect From Johnson & Johnson's Q2 Earnings - Johnson & Johnson - Benzinga
Benzinga 2d
Johnson & Johnson's Outlook Clouded By $2 Billion Headwind

Johnson & Johnson JNJ is set to release its second-quarter earnings on Wednesday, July 16. According to Benzinga Pro data, analysts estimate adjusted earnings o...

Johnson & Johnson's Outlook Clouded By $2 Billion Headwind

Analyst ratings

56%

of 25 ratings
Buy
44%
Hold
56%
Sell
0%

More JNJ News

Seeking Alpha 3d
J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug

A U.S. appeals court has sided with Johnson & Johnson (NYSE:JNJ) in a patent dispute with Viatris (NASDAQ:VTRS) and Teva Pharmaceutical (NYSE:TEVA) over the com...

J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug
Simply Wall St 4d
Johnson & Johnson Submits sNDA For Schizophrenia Drug CAPLYTA® To FDA

submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia relapse, marking a significant step in expanding its mental health p...

Johnson & Johnson Submits sNDA For Schizophrenia Drug CAPLYTA® To FDA
TipRanks 4d
Johnson & Johnson submits sNDA to U.S FDA for CAPLYTA

Johnson & Johnson announced the submission of a supplemental New Drug Application, sNDA, to the U.S. Food and Drug Administration, FDA, based upon long-term dat...

TipRanks 4d
Nanobiotix announces regulatory harmonization, new patent for JNJ-1900

Nanobiotix (NBTX) announced two developments related to radioenhancer JNJ-1900, which is licensed by Janssen Pharmaceutica, a Johnson & Johnson (JNJ) company. H...

TipRanks 5d
Balanced Outlook on Johnson & Johnson: MedTech Growth vs. Pharmaceutical Challenges

Analyst Larry Biegelsen from Wells Fargo maintained a Hold rating on Johnson & Johnson and keeping the price target at $170.00. Don’t Miss TipRanks’ Half-Year...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.